[1] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[2] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[3] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[4] |
ZHAO Yufang, SHI Wei, YANG Shengnan, LIU Zhien, LEI Wenpu, ZHANG Yanan, ZHAO Ke, GUO Hao.
983 Adverse Reaction Reports of Oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 645-648.
|
[5] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[6] |
WANG Jiaqing, WANG Qi, LIU Tongtong, ZHANG Dongjie, CHEN Qi, MEI Shenghui, NING Xiao.
Determination of Linezolid Concentrations in Plasma with HPLC-MS/MS Method
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 377-380.
|
[7] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[8] |
ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting.
159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.
|
[9] |
HU Kun, HUANG Weiguo, LEI Lili, PANG Xiaocong, ZHOU Ying, CUI Yimin.
One Case of Bone Marrow Suppression Caused by Azathioprine Tablets in a Patient with TPMT Heterozygous Mutation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 337-340.
|
[10] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
[11] |
YANG Shengxi, XU Juntong, TU Wenlian.
Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.
|
[12] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[13] |
YU Wenlu, ZHANG Hong.
Research Progress in Applications of Strychnine Semen in Orthopedics and Traumatology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 116-120.
|
[14] |
CAO Yin, ZHOU Xuan, DAI Biao, DENG Yiyun, YAN Chunyu, SHAN Feng, XIA Qingrong, LIANG Jun.
A UPLC-MS/MS method for determination of human serum trazodone concentration and its clinical individualized medications
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 991-997.
|
[15] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|